

*al.*, pages 4-10 of Miyata, *et al.*, and pages 5-14 of Inouye, *et al.* (all cited in the Action) carefully and cannot find any disclosure of such elements as a primer binding site, a primer binding site that is located in a 3' position relative to an inverted tandem repeat, a sequence complementary to a sequence of interest that is flanked by 3' and 5' complementary sequences comprising an inverted tandem repeat, or even the production of ssDNA *in vivo*, all as called out in claim 7. Applicant did not intend to offend by asking for such guidance in the previous Response and apologizes if any offense was taken; Applicant instead intended merely to request information in attempt to advance the prosecution of the application.

Applicant therefore traverses the §102 rejection of claim 7 of the present application because the claim elements listed in the previous paragraph are not disclosed in the cited references. Similarly, Applicant traverses the §102 rejections of claims 9-11 and 13-15 because those claims are dependent upon a main claim that it not anticipated.

Consideration of the remarks set out herein, reconsideration and withdrawal of the rejection, allowance of the claims, and passage of the application to issuance are respectfully requested. In the event there are questions, it is respectfully requested that Applicant's counsel be contacted at the address and telephone number set out below.

Respectfully submitted,



Mark R. Wisner

Registration No. 30,603

Wisner & Associates

2925 Briarpark, Suite 930

Houston, TX 77042

Telephone: (713) 785-0555

Facsimile: (713) 785-0561

ATTORNEY FOR APPLICANT

Date: June 7, 2002